Testing for the diagnosis of acute myocardial infarction and other diseases included in the spectrum of the "acute coronary syndrome" is rapidly changing from the traditional enzymatic assays to mass measurement bf more specific and sensitive markers (cardiac troponins, CK-MB and myoglobin). Several questions have arisen since the introduction of these new markers into the clinical setting: the choice of strategies for optimizing the utilization of biochemical assays combining different (early and specific) markers, a rationale for sampling specimens and the identification of clinically useful turnaround times. In particular, for achieving the last goal, attention has been directed toward near-patient testing for cardiac markers in addition to, or as a replacement for, traditional diagnostic methodologies. While qualitative methods for measuring cardiac markers at the bedside have some limitations which compromise their clinical usefulness, new quantitative devices offer a real alternative to decentralized testing. Regulatory and quality management issues related to near-patient testing, as well as the performance of recently introduced devices for a decentralized measurement of cardiac markers are reviewed.

Cardiac markers: centralized or decentralized testing?

PLEBANI, MARIO;ZANINOTTO, MARTINA
2000

Abstract

Testing for the diagnosis of acute myocardial infarction and other diseases included in the spectrum of the "acute coronary syndrome" is rapidly changing from the traditional enzymatic assays to mass measurement bf more specific and sensitive markers (cardiac troponins, CK-MB and myoglobin). Several questions have arisen since the introduction of these new markers into the clinical setting: the choice of strategies for optimizing the utilization of biochemical assays combining different (early and specific) markers, a rationale for sampling specimens and the identification of clinically useful turnaround times. In particular, for achieving the last goal, attention has been directed toward near-patient testing for cardiac markers in addition to, or as a replacement for, traditional diagnostic methodologies. While qualitative methods for measuring cardiac markers at the bedside have some limitations which compromise their clinical usefulness, new quantitative devices offer a real alternative to decentralized testing. Regulatory and quality management issues related to near-patient testing, as well as the performance of recently introduced devices for a decentralized measurement of cardiac markers are reviewed.
File in questo prodotto:
File Dimensione Formato  
10.1515_cclm.1999.162.pdf

accesso aperto

Tipologia: Published (publisher's version)
Licenza: Accesso libero
Dimensione 141.81 kB
Formato Adobe PDF
141.81 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/1480838
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact